-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MC-150 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MC-150 in Diffuse Large B-Cell Lymphoma Drug Details: MC-1-50 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MC-150 in B-Cell Non-Hodgkin Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MC-150 in B-Cell Non-Hodgkin Lymphoma Drug Details: MC-1-50 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MC-232 in Plaque Psoriasis (Psoriasis Vulgaris)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MC-232 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: MC-232 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MC-150 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MC-150 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drug Details: MC-1-50 is under...
-
Product Insights
![]()
MC 72 Field, United States
MC 72 upstream field is located in Central Planning Area, United States. The upstream field is owned by ILX Prospect Rampart LLC (15%); Kosmos Energy Gulf of Mexico Operations LLC (30%); Ridgewood Rampart LLC (15%); Talos Petroleum LLC (0%); Talos Resources LLC (40%). It is operated by Talos Petroleum LLC. The project started its operations in 1996. MC 72 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs...
-
Product Insights
![]()
Longhorn MC 503 Field, United States
Longhorn MC 503 upstream field is located in Central Planning Area, United States. The upstream field is owned by CNOOC Petroleum Offshore USA Inc (25%); Eni Petroleum US LLC (75%); Eni Us Operating Co Inc (0%). It is operated by Eni Us Operating Co Inc. The project started its operations in 2009. Longhorn MC 503 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location,...
-
Product Insights
New![]()
Mitsubishi Amazon Japan Solar PV Park
Mitsubishi Amazon Japan Solar PV Park is a solar PV project located in Japan. The project is owned by MC Retail Energy Co Ltd and is developed by West Holdings Corp. The project is at the permitting stage. Empower your strategies with our Mitsubishi Amazon Japan Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
New![]()
Tavan Tolgoi Coal Fired Power Plant
Tavan Tolgoi Coal Fired Power Plant is a thermal project located in Omnogovi, Mongolia. The project is owned and being developed by Marubeni Corp; MCS International LLC. The project is at the permitting stage. Empower your strategies with our Tavan Tolgoi Coal Fired Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Triheptanoin in Medium-Chain Acyl-CoA Dehydrogenase Deficiency
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Triheptanoin in Medium-Chain Acyl-CoA Dehydrogenase Deficiency Drug Details: Triheptanoin (Dojolvi) is a triglyceride. It is...
-
Product Insights
New![]()
Zhireken Mine
The Zhireken Mine is a molybdenum mine in Russia. It is currently in operation. Empower your strategies with our Zhireken Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital information...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.